- Home
- VTGN vs CYCC Comparison
VTGN vs CYCC Comparison
Compare VTGN & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- CYCC
- Stock Information
- Founded
- VTGN 1998
- CYCC 1992
- Country
- VTGN United States
- CYCC Malaysia
- Employees
- VTGN N/A
- CYCC N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- VTGN Health Care
- CYCC Health Care
- Exchange
- VTGN Nasdaq
- CYCC Nasdaq
- Market Cap
- VTGN 62.9M
- CYCC 61.2M
- IPO Year
- VTGN N/A
- CYCC N/A
- Fundamental
- Price
- VTGN $2.36
- CYCC $0.37
- Analyst Decision
- VTGN
- CYCC
- Analyst Count
- VTGN 0
- CYCC 0
- Target Price
- VTGN N/A
- CYCC N/A
- AVG Volume (30 Days)
- VTGN 153.9K
- CYCC 823.5K
- Earning Date
- VTGN 06-17-2025
- CYCC 05-15-2025
- Dividend Yield
- VTGN N/A
- CYCC 648.65%
- EPS Growth
- VTGN N/A
- CYCC N/A
- EPS
- VTGN N/A
- CYCC N/A
- Revenue
- VTGN $698,000.00
- CYCC $14,000.00
- Revenue This Year
- VTGN N/A
- CYCC $137.21
- Revenue Next Year
- VTGN N/A
- CYCC N/A
- P/E Ratio
- VTGN N/A
- CYCC N/A
- Revenue Growth
- VTGN N/A
- CYCC N/A
- 52 Week Low
- VTGN $1.90
- CYCC $0.35
- 52 Week High
- VTGN $4.21
- CYCC $39.84
- Technical
- Relative Strength Index (RSI)
- VTGN 47.43
- CYCC 22.52
- Support Level
- VTGN $2.32
- CYCC $1.36
- Resistance Level
- VTGN $2.63
- CYCC $1.73
- Average True Range (ATR)
- VTGN 0.13
- CYCC 0.31
- MACD
- VTGN -0.01
- CYCC -0.07
- Stochastic Oscillator
- VTGN 14.29
- CYCC 0.96
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.